Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Filter by Categories
Biosimilars Deals 2023
Biosimilars Deals 2024
Other Podcasts
Other Updates
Our Awards
Patent Case Summaries
Patent Litigation
Trade Marks

Dr Reddy Launches its First UK Biosimilar (bevacizumab) 5 Years After Indian Launch and 6 Years After First Bevacizumab UK Biosimilar Approval

Mar 19, 2024

On 19 March 2024, Dr. Reddy’s announced the launch of its Versavo® (bevacizumab) in the UK. Versavo® is a biosimilar to Genentech’s Avastin®(bevacizumab) and is indicated for the treatment of several types of cancers, including metastatic colorectal cancer, advanced non-squamous non-small cell lung cancer, recurrent glioblastoma, metastatic renal cell carcinoma, advanced cervical cancer, ovarian cancer and metastatic breast cancer.   Versavo® is Dr. Reddy’s first biosimilar product to be approved and launched in the UK and is supplied in 100mg and 400mg single use vials.

Versavo® was launched in India just under 5 years earlier, in August 2019.   The first bevacizumab biosimilar was approved in the UK in January 2018  resulting in Dr Reddy’s launching its biosimilar more than 6 years after the first approved biosimilar.